ATE537842T1 - Zusammesetzungen von cg250 und il-2 oder von cg250 und ifn-alpha zur krebsbehandlung des nierenzell karzinoms - Google Patents

Zusammesetzungen von cg250 und il-2 oder von cg250 und ifn-alpha zur krebsbehandlung des nierenzell karzinoms

Info

Publication number
ATE537842T1
ATE537842T1 AT03740312T AT03740312T ATE537842T1 AT E537842 T1 ATE537842 T1 AT E537842T1 AT 03740312 T AT03740312 T AT 03740312T AT 03740312 T AT03740312 T AT 03740312T AT E537842 T1 ATE537842 T1 AT E537842T1
Authority
AT
Austria
Prior art keywords
cytokine
ifn
alpha
compositions
cell carcinoma
Prior art date
Application number
AT03740312T
Other languages
English (en)
Inventor
Sven Warnaar
Stefan Ullrich
Original Assignee
Wilex Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wilex Ag filed Critical Wilex Ag
Application granted granted Critical
Publication of ATE537842T1 publication Critical patent/ATE537842T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AT03740312T 2002-07-01 2003-06-23 Zusammesetzungen von cg250 und il-2 oder von cg250 und ifn-alpha zur krebsbehandlung des nierenzell karzinoms ATE537842T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39231102P 2002-07-01 2002-07-01
PCT/EP2003/006591 WO2004002526A1 (en) 2002-07-01 2003-06-23 Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas

Publications (1)

Publication Number Publication Date
ATE537842T1 true ATE537842T1 (de) 2012-01-15

Family

ID=30000842

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03740312T ATE537842T1 (de) 2002-07-01 2003-06-23 Zusammesetzungen von cg250 und il-2 oder von cg250 und ifn-alpha zur krebsbehandlung des nierenzell karzinoms

Country Status (8)

Country Link
US (2) US7632496B2 (de)
EP (2) EP2357005A1 (de)
JP (3) JP5408833B2 (de)
AT (1) ATE537842T1 (de)
AU (2) AU2003280442B2 (de)
CA (1) CA2492057A1 (de)
ES (1) ES2377396T3 (de)
WO (1) WO2004002526A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077081A1 (en) * 2001-02-07 2004-04-22 Egbert Oosterwijk Hybridoma cell line g250 and its use for producing monoclonal antibodies
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
US7632496B2 (en) * 2002-07-01 2009-12-15 Wilex Ag Co-administration of cG250 and IL-2 or IFN-α for treating cancer such as renal cell carcinomas
DK2497497T3 (en) 2004-07-02 2017-08-14 Wilex Ag Improved adjuvant treatment of G250-expressing tumors
EP1846020B1 (de) * 2005-01-27 2013-08-21 Novartis Vaccines and Diagnostics, Inc. Verfahren zur behandlung von nierenzellenkarzinom
US8466263B2 (en) 2005-12-02 2013-06-18 Dana-Farber Cancer Institute, Inc. Carbonic anhydrase IX (G250) anitbodies
US8053430B2 (en) * 2008-10-06 2011-11-08 Haraldsson Boerje Treatment of renal cell carcinoma
CA2794555A1 (en) 2010-04-01 2011-10-06 Oncorena Ab Improved treatment of renal cell carcinoma
US9844582B2 (en) * 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
WO2017139570A1 (en) 2016-02-12 2017-08-17 Massachusetts Intitute Of Technology Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccinne
WO2020154032A1 (en) 2019-01-23 2020-07-30 Massachusetts Institute Of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
AU6032786A (en) 1985-07-25 1987-01-29 University Of Minnesota Detection, imaging and therapy of renal cell carcinoma with monoclonal antibodies in vivo
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5104652A (en) 1986-11-13 1992-04-14 Sloan-Kettering Institute For Cancer Research Compositions and method for treatment of cancer using monoclonal antibody against GD3 ganglioside together with IL-2
EP0366707A1 (de) 1987-05-06 1990-05-09 OOSTERWIJK, Egbert Monoklonale antikörper gegen nierenzellen-karzinom
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5830452A (en) 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2
US5955075A (en) * 1992-03-11 1999-09-21 Institute Of Virology, Slovak Academy Of Sciences Method of inhibiting tumor growth using antibodies to MN protein
US5387676A (en) 1992-03-11 1995-02-07 Ciba Corning Diagnostics Corp. MN gene and protein
US6204370B1 (en) * 1992-03-11 2001-03-20 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6027887A (en) * 1992-03-11 2000-02-22 Institute Of Virology, Solvak Academy Of Sciences MN gene and protein
US5989838A (en) * 1992-03-11 1999-11-23 Institute Of Virology, Slovak Academy Of Sciences Immunological methods of detecting MN proteins and MN polypeptides
US6774117B1 (en) * 1992-03-11 2004-08-10 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6069242A (en) * 1992-03-11 2000-05-30 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6297041B1 (en) * 1992-03-11 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6093548A (en) * 1992-03-11 2000-07-25 Institute Of Virology, Slovak Academy Of Sciences Detection and quantitation of MN-specific antibodies.
US6297051B1 (en) * 1997-01-24 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US5972353A (en) * 1992-03-11 1999-10-26 Institute Of Virology, Slovak Academy Of Sciences MN proteins, polypeptides, fusion proteins and fusion polypeptides
US5981711A (en) * 1992-03-11 1999-11-09 Institute Of Virology, Slovak Academy Of Sciences MN-specific antibodies and hybridomas
US6509313B1 (en) 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
US6417337B1 (en) 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
US6239235B1 (en) * 1997-07-15 2001-05-29 Phillips Petroleum Company High solids slurry polymerization
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
ES2296412T3 (es) 1998-10-23 2008-04-16 Institute Of Virology Gen y proteina mn.
FR2793497B1 (fr) 1999-05-10 2003-04-18 Centre Nat Rech Scient Anticorps monoclonal dirige contre les cellules de carcinome renal humain
JP2003531568A (ja) 1999-07-06 2003-10-28 ゴット−エー−ジェーン・エービー 組換え型アデノウイルス
US7306801B2 (en) 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
EP1299542A2 (de) 2000-06-06 2003-04-09 Idec Pharmaceuticals Corporation Nichtagonistische antikörper gegen humanes gp39, zusammensetzungen und deren verwendungen
GB0017720D0 (en) * 2000-07-19 2000-09-06 Got A Gene Ab Modified virus
US20040077081A1 (en) * 2001-02-07 2004-04-22 Egbert Oosterwijk Hybridoma cell line g250 and its use for producing monoclonal antibodies
ATE337395T1 (de) 2001-02-07 2006-09-15 Wilex Ag Hybridomzelllinie g250 und deren verwendung zur herstellung monoklonaler antikörper
EP1392360B1 (de) * 2001-06-01 2011-11-30 Cornell Research Foundation, Inc. Modifizierte antikörper gegen prostata-spezifisches membranantigen und ihre verwendungen
US7714113B2 (en) * 2002-02-13 2010-05-11 Ludwig Institute For Cancer Research Fusion proteins of humanized g250 specific antibodies and uses thereof
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
US7632496B2 (en) 2002-07-01 2009-12-15 Wilex Ag Co-administration of cG250 and IL-2 or IFN-α for treating cancer such as renal cell carcinomas
DK2497497T3 (en) * 2004-07-02 2017-08-14 Wilex Ag Improved adjuvant treatment of G250-expressing tumors
EP1749839A1 (de) 2005-07-22 2007-02-07 Novoplant GmbH Antigen-bindende Polypeptide gegen F4 (K88) fimbriae
AU2006301492B2 (en) * 2005-10-11 2011-06-09 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
WO2008091798A2 (en) 2007-01-22 2008-07-31 Xencor, Inc. Optimized ca9 antibodies and methods of using the same
US8492520B2 (en) * 2007-11-02 2013-07-23 Wilex Ag Binding epitopes for G250 antibody

Also Published As

Publication number Publication date
EP1524995A1 (de) 2005-04-27
EP2357005A1 (de) 2011-08-17
JP2005531620A (ja) 2005-10-20
EP1524995B1 (de) 2011-12-21
US20100008888A1 (en) 2010-01-14
JP2011068696A (ja) 2011-04-07
ES2377396T3 (es) 2012-03-27
US8828381B2 (en) 2014-09-09
US7632496B2 (en) 2009-12-15
AU2003280442B2 (en) 2009-02-05
AU2009201236B2 (en) 2011-05-26
US20050261178A1 (en) 2005-11-24
JP2014043473A (ja) 2014-03-13
AU2009201236A1 (en) 2009-04-23
WO2004002526A1 (en) 2004-01-08
AU2003280442A1 (en) 2004-01-19
JP5408833B2 (ja) 2014-02-05
CA2492057A1 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
CY1110803T1 (el) Μεθοδοι θεραπειας για καρκινους που εκφραζουν to cd40 αντιγονο
HK1106736A1 (en) Combination therapy comprising anti-cd20 and anti-cd40 antibodies for the treatment of b cell-related cancers
ATE537842T1 (de) Zusammesetzungen von cg250 und il-2 oder von cg250 und ifn-alpha zur krebsbehandlung des nierenzell karzinoms
NO20071585L (no) Ny anvendelse av peptidforbindelser for behandling av benkreftsmerte, kjemoterapi- og nucleosidfremkalt smerte
MXPA03010121A (es) Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales.
ATE412771T1 (de) Verfahren zur modulation der tubulindeacetylase- aktivität
IS8432A (is) Mótefni sem bindast viðtaka hvítfrumuboða-4
DE60238560D1 (de) Kombinationen aus anti-dr5-antikörpern und anti-dr4-antikörpern und weiteren therapeutischen agentien
BR0313282A (pt) Composições de inibidor seletivo de ciclooxigenase-2 e um inibidor de anidrase carbÈnica para o tratamento de neoplasia
TW200518752A (en) Combinations of drugs for the treatment of neoplasms
DK1169059T3 (da) Docetaxel i kombination med rhuMAb HER2 til behandling af cancere
CY1113287T1 (el) Μεθοδοι αγωγης του καρκινου χρησιμοποιωντας il-21 και θεραπεια με μονοκλωνικα αντισωματα
MXPA04003674A (es) Uso mejorado de compuesto antitumoral en terapia de cancer.
MY146533A (en) Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
BR0207443A (pt) Método e forma de dosagem para o tratamento de tumores pela administração de tegafur, uracila, ácido folìnico, paclitaxel e carboplatina
DK1684770T3 (da) Oligo-beta-(1, 3) -glucan og monoklonale antistoffer mod kræft
EA200801731A1 (ru) Составы и способы лечения тробмоцитемии
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
DE60331827D1 (de) Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren
WO2003061571A3 (en) Combination il-2/anti-herz antibody therapy for cancers characterized by overexpression of the her2 receptor protein
ATE545423T1 (de) Mittel zur behandlung von lungenkrebs
EA200201154A1 (ru) Бис(n,n'-бис(2-галоэтил)амино)фосфороамидаты в качестве противоопухолевых агентов
WO2004017919A3 (en) Use of mullerian inhibiting substance and interferon for treating tumors
ATE490981T1 (de) Criptospezifische antikörper